<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Task Force 3: long-term care of heart transplant recipients. In: the International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G. Task Force 3: long-term care of heart transplant recipients. In: the International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):933-44.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Complications of transplanted heart  (996.83); Diagnostic ultrasound of heart  (88.72); Heart transplantation  (37.51); Venereal disease, unspecified  (099.9)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Adrenal Cortex Hormones ; Anesthesia ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Anti-Bacterial Agents ; Antibiotic Prophylaxis ; Automobile Driving ; Calcineurin Inhibitors ; Calcium Channel Blockers ; Calcium, Dietary ; Continuity of Patient Care ; Contraception ; Coronary Angiography ; Diabetes Mellitus ; Diphosphonates ; Drug-Eluting Stents ; Echocardiography ; Erectile Dysfunction ; Exercise ; Follow-Up Studies ; Glomerular Filtration Rate ; Graft Rejection ; Heart Transplantation ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypertension ; Immunosuppression ; Immunosuppressive Agents ; Kidney Transplantation ; Life Style ; Long-Term Care ; Medication Adherence ; Medication Therapy Management ; Myocardial Perfusion Imaging ; Myocardial Revascularization ; Patient Care Team ; Percutaneous Coronary Intervention ; Pregnancy ; Radiography ; Rehabilitation ; Reproductive Health ; Return to Work ; Sexually Transmitted Diseases ; Ultrasonography ; Vitamin D "/><FieldValue Value="MTH: Adherence To Medication Regime ; Adrenal Cortex Hormones ; Anesthesia procedures ; Angiotensin Receptor Antagonists ; Angiotensin-Converting Enzyme Inhibitors ; Anti-Bacterial Agents ; Antibiotic Prophylaxis ; Calcineurin inhibitor ; Calcium Channel Blockers ; Calcium, Dietary ; Chronic Kidney Diseases ; Contraceptive methods ; Coronary angiography ; Diabetes Mellitus ; Diphosphonates ; Echocardiography ; Erectile dysfunction ; Exercise ; Fit for work with restrictions (finding) ; follow-up ; Glomerular Filtration Rate ; Graft Rejection ; Heart Transplantation ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypertensive disease ; Immunosuppressive Agents ; Kidney Transplantation ; Life Style ; long-term care ; Percutaneous Coronary Intervention ; Pregnancy ; Radiographic imaging procedure ; Rehabilitation therapy ; Screening for cancer ; Sexually Transmitted Diseases ; Therapeutic immunosuppression ; Ultrasonography ; Vitamin D "/><FieldValue Value="PDQ: anesthesia ; immunosuppression ; kidney transplantation ; ultrasonography "/><FieldValue Value="SNOMEDCT_US: Administration of anesthesia  (399097000); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antibiotic prophylaxis  (422181004); Calcineurin inhibitor  (416587008); Calcineurin inhibitor  (416798007); Calcium channel blocker  (373304005); Calcium channel blocker  (48698004); Cardiac transplant disorder  (233932001); Contraception  (13197004); Coronary angiography  (33367005); Corticoid preparation  (21568003); Corticoid preparation  (79440004); CT angiography of coronary arteries  (419545005); Diabetes clinical management plan  (412777005); Diabetes mellitus  (73211009); Diphosphonate  (372907000); Diphosphonate  (96281001); Driving  (129060000); Drug eluting stent  (411191007); Echocardiography  (40701008); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fit for work with restrictions  (225891002); Glomerular filtration rate  (80274001); Graft rejection  (72627004); Heart transplant failure and rejection  (213151004); HMG-CoA reductase inhibitor  (372912004); HMG-CoA reductase inhibitor  (96302009); Hypertensive disorder  (38341003); Immunosuppressant  (372823004); Immunosuppressant  (69431002); Immunosuppressive therapy  (86553008); Impotence  (397803000); Life style  (134436002); Life style  (60134006); Medication compliance  (182884001); Medication compliance  (418633004); Muscle strength exercise  (266741004); Myocardial revascularization  (174911007); Myocardial revascularization  (275227003); Myocardial revascularization  (81266008); Percutaneous coronary intervention  (415070008); Pregnancy  (289908002); Radiographic imaging procedure  (363680008); Rehabilitation therapy  (52052004); Returned to work  (266962006); Screening for cancer  (15886004); Sexually transmitted infectious disease  (8098009); Transplant of kidney  (70536003); Transplantation of heart  (32413006); Ultrasonography  (16310003); Ultrasonography  (278292003); Ultrasonography  (359659005); Vitamin D  (11563006); Vitamin D  (30178006)"/><FieldValue Value="SPN: SYSTEM, IMAGING, PULSED DOPPLER, ULTRASONIC "/><FieldValue Value="UMD: Densitometers, Bone, Isotope, Dual-Photon Absorptiometry  (17-150); Radiographic Systems  (18-429); Scanning Systems, Ultrasonic  (14-278)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diseases or conditions requiring heart transplantation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Complications of heart transplantation including cardiac allograft vasculopathy and chronic adverse effects of immunosuppression (neurotoxicity, renal insufficiency, hypertension, bone disease, diabetes, and malignancy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reproductive health following heart transplantation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;General physical and psychological health following heart transplantation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Prevention" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Pediatrics" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Psychiatry" /><FieldValue Value="Psychology" /><FieldValue Value="Surgery" /><FieldValue Value="Thoracic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Nurses" /><FieldValue Value="Occupational Therapists" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To address the myriad of clinical issues occurring long-term after heart transplantation, including cardiac allograft vasculopathy, the chronic adverse effects of immunosuppression (neurotoxicity, renal insufficiency, hypertension, bone disease, diabetes and malignancy), as well as reproductive health, exercise, psychologic problems, return to work, and operation of motor vehicles after heart transplantation&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Pediatric and adult transplant recipients, including women who become pregnant after receiving a heart transplant&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Minimization of immunosuppression (corticosteroid [CS] withdrawal, lowering calcineurin inhibitor [CNI] levels) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of neurologic complications (reduction of CNI doses or substitution with a proliferation signal inhibitor [PSI]) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Diagnosis and management of cardiac allograft vasculopathy (CAV)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Primary prevention of CAV, including statin therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Coronary angiography, including computed tomography (CT) coronary angiography &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Intravascular ultrasound &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of a PSI &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Treadmill or dobutamine stress echocardiography and myocardial perfusion imaging &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Percutaneous coronary intervention with drug-eluting stents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Surgical revascularization &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Retransplantation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Ultrafast CT &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screening for malignancies (breast, colon, prostate, skin cancer) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of chronic kidney disease (CKD)&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Estimation of glomerular filtration rate &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reducing CNI exposure &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Minimization of CSs &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Interventions to slow progression of CKD and to manage anemia &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Kidney transplantation &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Control of hypertension (calcium channel blockers [CCBs]) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of diabetes mellitus (prevention, early detection, and appropriate therapy) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of various complications of chronic immunosuppression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of hypertension&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Lifestyle modifications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Drug therapy (CCBs, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Prophylaxis for CS-induced bone disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Calcium and vitamin D intake &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Weight-bearing and muscle-strengthening exercise &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reduction or withdrawal of CS &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bisphosphonate therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Spine radiographs &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Assessment of bone mineral density by dual energy x-ray absorptiometry (DEXA) scan &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Care of the pregnant heart transplant recipient&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Determining cardiac status &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Considerations for immunosuppressive drug use &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Contraception after heart transplantation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of sexually transmitted infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of erectile dysfunction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise and physical rehabilitation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of intercurrent surgery (anesthesia, antibiotic prophylaxis, immunosuppression dosage) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Returning to work and occupational restrictions &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Returning to operating a motor vehicle &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considerations for cardiac retransplantation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Endocarditis prophylaxis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency of routine tests and clinic visits (lifelong follow-up) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Considerations for psychological issues particularly related to adherence to medical therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management of the transition from pediatric to adult care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Principles of shared care after heart transplantation &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Survival rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rejection rate &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Rate of cardiac allograft vasculopathy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of immunosuppression &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Medline dating from January 1980 to May 2010 was used for all searches. The guidelines were broken down into specific topics and each topic/chapter was searched independently. Thus, the searches were specific to the chapter/topic. Each topic did not have extensive literature available; therefore, no studies were excluded based on inclusion/exclusion criteria. All studies were considered.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;: Data derived from multiple randomized clinical trials or meta-analyses&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;: Data derived from a single randomized clinical trial or large non-randomized studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;: Consensus of opinion of the experts and/or small studies, retrospective studies, registries&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The International Society for Heart and Lung Transplantation (ISHLT) has made an unprecedented commitment to convene experts in all areas of heart transplantation to develop practice guidelines for the care of heart transplant recipients. After a vast effort involving 40 writers from 9 countries worldwide, the ISHLT Guidelines for the Care of Heart Transplant Recipients were completed.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;It is important to note that each task force was co-chaired by a pediatric heart transplant physician who had the specific mandate to highlight issues unique to the pediatric heart transplant population and to ensure their adequate representation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As the reader will undoubtedly observe, most of the recommendations only achieve a Level of Evidence C, indicating that these recommendations are based on expert consensus and not on randomized controlled clinical trials. A concerted effort was also made to highlight the numerous gaps in evidence pertaining to many aspects of the care of heart transplant recipients. This lack of &quot;evidence-based&quot; recommendations is mostly due to the limited number of heart transplant recipients worldwide.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Consensus Achievement&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Consensus can be achieved for recommendations without much discussion when strong evidence exists. However, the Writing Group must also critically consider the applicability of the recommendations to a specific field or area. For example, recommendations on particular treatments based on trials carried out in patients aged 70 years or younger cannot be extended to patients older than 70 years.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In controversial areas, or in issues without evidence other than usual clinical practice, different processes can achieve consensus:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Expert panel discussion and common sense &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quantification of expert opinions. These are interesting but time-consuming methods. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Class of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful and effective&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Conflicting evidence and/or divergence of opinion about the usefulness/efficacy of the treatment or procedure&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: Weight of evidence/opinion is in favor of usefulness/efficacy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIb&lt;/strong&gt;: Usefulness/efficacy is less well established by evidence/opinion&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence or general agreement that the treatment or procedure is not useful or effective and in some cases may be harmful&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When the guidelines are almost finalized and ready for review, a review coordinator is appointed within the Committee. This review coordinator, in conjunction with the Committee and the Writing Group choose additional document reviewers. These reviewers will have to disclose any potential conflicts of interest they may have and send in their review comments within a set timeframe. If they do not follow these procedures, they will not appear in the final document in the reviewers' list.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The Writing Group integrates the reviewers' comments and returns the revised version for Committee approval (there can be several rounds of this process). English language reviewers and proofreaders are called upon when necessary after completion of all revisions. The final approval of the various documents is given by the Committee before creating the final version that will go to the Standards and Guidelines (S&amp;amp;G) committee and, subsequently, the Board of Directors for final approval.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The class of the recommendation (I, II, IIa, IIb, III) and the level of the evidence (A-C) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 1: Minimization of Immunosuppression&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Minimization of Immunosuppression&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Corticosteroid (CS) withdrawal can be successfully achieved 3 to 6 months after heart transplant (HT) in many low-risk patients (those without circulating anti-human leukocyte antigen [HLA] antibodies, non-multiparous women, those without a history of rejection, and older HT recipients).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lower levels of calcineurin inhibitor (CNI) in HT recipients should be sought when CNI are used in conjunction with mycophenolate mofetil (MMF) (compared with azathioprine [AZA]) because with this combination lower levels are safe and associated with lower rejection rates as well as improved renal function.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;A proliferation signal inhibitor (PSI) may be substituted for CNI later than 6 months after HT to reduce CNI-related nephrotoxicity and cardiac allograft vasculopathy (CAV) in low-risk recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;CNI monotherapy with early CS withdrawal may be considered in highly selected individuals. This strategy has been associated with acceptable short-term outcomes in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In pediatric HT recipients, minimization of immunosuppression by CS withdrawal is common practice and appears safe, with the majority of children being free of CS by 5 years after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Due to variable pharmacokinetics in children, strategies for minimization of immunosuppression in the pediatric population may require a greater reliance on drug level monitoring than in adults.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of PSI may be considered in pediatric HT recipients to reduce CAV and nephrotoxicity, but insufficient data are available on the effects of PSI in children.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;In HT recipients, substitution of PSI for MMF for the specific purpose of lowering CNI exposure to reduce CNI-related nephrotoxicity is not recommended due to the interaction between CNI and PSI, which enhances CNI nephrotoxicity.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Substitution of a PSI for MMF earlier than 3 months after HT is not recommended due to a higher risk of rejection as well as delayed wound healing.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 2: Management of Neurologic Complications after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Management of Neurologic Complications after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Management of HT recipients with seizures should include reduction of CNI doses (taking into consideration the risk of inadequate immunosuppression) and correction of hypomagnesemia, if present.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The occurrence of encephalopathy late after HT should prompt neurologic consultation and imaging to identify possible underlying etiologies.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Posterior reversible leukoencephalopathy (PRES) in HT recipients should be managed with a reduction of CNI doses or substitution with an alternative CNI.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Heart transplant recipients who continue to experience seizures after a reduction in the CNI dose may benefit from CNI withdrawal and substitution with a PSI (sirolimus [SRL], everolimus [EVL]).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 3: Cardiac Allograft Vasculopathy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Diagnosis and Management of Cardiac Allograft Vasculopathy&lt;/strong&gt; (See Table 13 in the original guideline document.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Primary prevention of CAV in HT recipients should include strict control of cardiovascular risk factors (hypertension, diabetes, hyperlipidemia, smoking, and obesity) as well as strategies for the prevention of cytomegalovirus (CMV) infection.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In HT recipients, statin therapy has been shown to reduce CAV and improve long-term outcomes regardless of lipid levels and should be considered for all HT recipients (adult and pediatric).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: A.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Annual or biannual coronary angiography should be considered to assess the development of CAV. Patients free of CAV at 3 to 5 years after HT, especially those with renal insufficiency, may undergo less frequent invasive evaluation.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up coronary angiography is recommended at 6 months after a percutaneous coronary intervention because of high restenosis rates in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Selective coronary angiography is the investigation of choice for the diagnosis of CAV in pediatric HT recipients. It should be performed at yearly or biannual intervals.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;A baseline coronary angiogram at 4 to 6 weeks after HT may be considered to exclude donor coronary artery disease.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Intravascular ultrasound (IVUS) in conjunction with coronary angiography with a baseline study at 4 to 6 weeks and at 1 year after HT is an option to exclude donor coronary artery disease, to detect rapidly progressive CAV, and provide prognostic information.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In HT recipients with established CAV, the substitution of MMF or AZA with a PSI can be considered.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A PSI can been used in pediatric HT recipients who develop CAV, but the effect of PSI on the progression of CAV in children is unknown.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;IVUS can be safely used in older pediatric HT recipients to assess CAV.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evaluation of coronary flow reserve in conjunction with coronary angiography may be useful for the detection of small-vessel coronary disease, which is a manifestation of CAV.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treadmill or dobutamine stress echocardiography and myocardial perfusion imaging may all be useful for the detection of CAV in HT recipients unable to undergo invasive evaluation. Non-invasive testing for CAV is technically possible in children.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percutaneous coronary intervention with drug-eluting stents is recommended in both adults and children with CAV and offers short-term palliation for appropriate discrete lesions.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical revascularization in HT recipients with CAV is an option in highly selected patients who have lesions amenable to surgical revascularization.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiac retransplantation may be considered in patients with severe CAV and absence of contraindications for repeat HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Ultrafast computed tomography (CT) for the detection of coronary calcium has been used mostly as an investigational tool for assessing CAV in HT recipients, but is being superseded by advances in CT angiography.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CT coronary angiography shows promise in the evaluation of CAV in HT recipients, although higher resting heart rates in these patients limit the technical quality of this study.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 4: Malignancy after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on the Approach to Malignancy after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommendations regarding screening for breast, colon, and prostate cancer in the general population should also be followed in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is recommended that HT recipients have close skin cancer surveillance, including education on preventive measures and yearly dermatologic examinations.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Initial evaluation and a therapeutic plan for post-transplant lymphoproliferative disorder (PTLD) in HT recipients should be done at the transplant center by physicians familiar with transplant-associated malignancies.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;There is no evidence to support a reduction in immunosuppression in patients with solid tumors unrelated to the lymphoid system. Maintenance immunosuppression should be continued unless there are specific reasons to reduce certain drugs, such as reduction of bone marrow-suppressive agents if leucopenia occurs.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Chronic immunosuppression should be minimized in HT recipients as possible, particularly in patients at high risk for malignancy.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 5: Chronic Kidney Disease after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Chronic Kidney Disease after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Estimation of glomerular filtration rate (GFR) with the modified diet in renal disease (MDRD) equation, urinalysis, and spot urine albumin/creatinine ratio should be obtained at least yearly after HT. Measurement of serum creatinine (sCr) for estimation of GFR should be obtained more often in patients with GFR &amp;lt;60 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;, and/or fast GFR decline in the past (&amp;gt;4 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; per year).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Although in children there is no consensus on the optimal method to estimate GFR, this measurement should be done and a urinalysis obtained at least yearly in pediatric HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart transplant recipients with an estimated GFR &amp;lt;30 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt;, proteinuria &amp;gt;500 mg/day (or urine albumin/creatinine ratio &amp;gt;500 mg/g), or rapidly declining GFR (&amp;gt;4 ml/min/1.73 m&lt;sup&gt;2&lt;/sup&gt; per year), should be referred to a nephrologist for management of metabolic abnormalities and other complications of renal insufficiency and consideration of renal transplantation.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In all HT recipients (adult and pediatric) with chronic kidney disease (CKD), CNI exposure should be lowered to the minimum level required for effective immunosuppression. In patients taking AZA, this may be achieved by conversion of AZA to MMF.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Owing to the potential for precipitating rejection, CNI-free regimens should be used with caution in HT recipients with significant renal insufficiency that persists despite CNI reduction.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In pediatric HT recipients, CS minimization or withdrawal should be attempted to avoid hypertension and subsequent CKD, as long as there is no clinical rejection. There are no strong data in adult HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interventions that have been proven to slow the progression of CKD in the general population should be considered in all HT recipients. These include strict glucose and blood pressure control and use of an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB). The American Diabetes Association (ADA) or the International Diabetes Federation Guidelines should be used to manage diabetes. Blood pressure should be treated according to the Joint National Committee VII or the European Society of Cardiology 2007 Guidelines.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In pediatric HT recipients, diabetes is rare. In contrast, hypertension is common, and adequate blood pressure control with a calcium channel blocker (CCB) or ACEI is warranted to avoid CKD.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hemoglobin (Hgb) levels should be measured at least annually in all HT patients with CKD. If anemia (Hgb &amp;lt;13.5 g/dl in adult men; &amp;lt;12 g/dl in adult women) is detected, iron status should be addressed and erythropoiesis-stimulating agents should be used to maintain Hgb levels between 11 and 13 g/dl.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Kidney transplantation should be considered the treatment of choice for all HT recipients (adult and pediatric) with end-stage renal disease who are appropriate candidates. Living donation should be considered.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;CCBs should be considered the antihypertensive drug of choice when optimal blood pressure control cannot be achieved with ACEI/ARB or when these drugs are contraindicated in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 6: Management of Diabetes Mellitus after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Management of Diabetes after HT&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Prevention, early detection, and appropriate therapy for diabetes should be considered as an important component of patient care after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients should be periodically screened for diabetes after HT by measuring fasting plasma glucose levels or with an oral glucose tolerance test (more sensitive screening test for pre-diabetic state) and glycosylated hemoglobin (HgbA&lt;sub&gt;1C&lt;/sub&gt;) determination, as appropriate. The frequency of screening will depend on risk factors and immunosuppressive therapy.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Therapies for short-term peri-operative and long-term chronic glycemic control in HT recipients should be based on American Diabetes Association recommendations.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Heart transplant recipients with diabetes should be counseled regarding weight control, diet and nutrition, and exercise.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pre-HT risk factors should be assessed, and diabetogenic immunosuppressive medications should be minimized whenever possible in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CS-sparing regimens and decreased CNI doses should be used as appropriate to prevent diabetes in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Associated cardiovascular risk factors (in addition to diabetes), such as hyperlipidemia and hypertension, should be managed aggressively in HT recipients. Annual measurements of lipids levels should be performed according to American Diabetes Association recommendations.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Annual screening should be performed for diabetic complications (ophthalmology, podiatry, peripheral vascular disease, etc.) in HT recipients with diabetes.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;An endocrinology consultation may be considered when a pre-diabetic state or diabetes is diagnosed in a HT recipient.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 7: Other Complications of Chronic Immunosuppression&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on the Management of Various Complications of Chronic Immunosuppression&lt;/strong&gt; (See Table 14 in the original guideline document.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommendations for addressing other complications of immunosuppression include regular screening for adverse events, minimizing drug doses, drug substitution, and drug withdrawal (as previously discussed), as well as initiating targeted therapies for a specific complication. For example, antihyperuricemic therapy and concurrent risk reduction may be used to prevent recurrent attacks of gout, whereas acquired cataracts require surgical intervention. It is important to assess for contraindications and drug interactions when medically treating complications of immunosuppression.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 8: Hypertension after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on the Management of Hypertension after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Because antihypertensive therapy in HT recipients has benefits similar to those in the general population, hypertension after HT should be treated to achieve the same goals recommended for the general population.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Lifestyle modifications, including weight loss, low-sodium diet, and exercise are appropriate adjuncts to facilitate control of blood pressure in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drug choice for treatment of hypertension in HT recipients is empiric and depends on blood pressure responses. CCBs are most widely used, but ACEI and ARB may be preferred in diabetic recipients, and a 2-drug regimen can include both CCB and ACEI/ARB.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Modification of risk factors such as diabetes and hyperlipidemia are appropriate as adjunctive treatment for hypertension in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Appropriate adjustment of immunosuppressive therapy, especially CS weaning, may be helpful in management of hypertension in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Hypertension is common in both adults and children after HT and can be assessed with ambulatory blood pressure monitoring.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 9: Prophylaxis for Corticosteroid-Induced Bone Disease&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Gaps in Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Bisphosphonates continue to suppress bone reabsorption after discontinuation of therapy. It is not known, however, if pre-operative administration of these drugs can prevent the increased bone loss that develops after HT with the introduction of CS.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The predictive role of bone mass density (BMD) measurement for fracture risk is unproven in HT recipients. Although several studies have described a beneficial effect of bisphosphonates and vitamin D analogues on bone density in adult HT recipients, none of these studies has been powered to detect a decrease in fracture rate. In addition, important issues that remain unresolved include which is the optimal bisphosphonate, the route and duration of administration, and whether therapy should be continuous or intermittent. More research is also needed to define appropriate indications for bisphosphonate therapy and the optimal agent, dose, and duration of use in pediatric patients.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The potential role in the HT population of the recombinant human parathyroid hormone (teriparatide), a bone-forming agent, and strontium ranelate, the first agent to stimulate bone formation while decreasing reabsorption, deserves investigation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Prophylaxis of Corticosteroid-Induced Bone Disease after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;All adult HT candidates should be screened for pre-existing bone disease, preferably at the time of placement on the waiting list. In adults, baseline BMD should be obtained with a dual energy x-ray absorptiometry (DEXA) scan of the lumbar spine and femoral neck.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The presence of low BMD or vertebral fractures should prompt evaluation and treatment of correctable secondary causes of osteoporosis, because significant improvement in BMD can be attained during the waiting period for HT. Bisphosphonates should be considered the treatment of choice.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All HT candidates and recipients should have the recommended daily allowance for calcium (1,000 &amp;ndash;1,500 mg, depending on age and menopausal status) and vitamin D (400&amp;ndash;1,000 IU, or as necessary to maintain serum 25-hydroxyvitamin D levels above 30 ng/ml = 75 nmol/L).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After HT, regular weight-bearing and muscle-strengthening exercises should be encouraged to reduce the risk of falls and fractures and to increase bone density.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In pediatric HT recipients, it is important to monitor growth and pubertal development and be alert to the development of signs and symptoms of bone disease.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reduction or withdrawal of CS in pediatric HT recipients should be considered in the absence of preceding rejection with close monitoring for clinical rejection.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After HT, children should be encouraged to increase physical activity; daily intake of calcium with vitamin D through diet or supplements should meet recommendations for age.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All adult HT recipients should begin antiresorptive therapy with bisphosphonates immediately after HT and continue it at least throughout the first post-operative year.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Bisphosphonates can be used to treat bone loss in long-term HT recipients and should be used in addition to calcium and vitamin D.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In pediatric HT recipients who have not reached bone maturity, bisphosphonates should be restricted to patients with reduction in bone mass density associated with low-trauma fractures or vertebral compression.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is reasonable to perform spine radiographs in all adult HT candidates to detect existing fractures.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After the first post-HT year, if glucocorticoids have been discontinued and BMD is relatively normal (T score &amp;ge;1.5), it is reasonable to stop bisphosphonates, while maintaining a high degree of vigilance for osteoporosis.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Proximal femur and lumbar spine BMD should be assessed by DEXA scanning in all adult patients 1 year after HT. Thereafter, annual reassessments are wise in patients receiving CS and/or bisphosphonate therapy. However, it should be kept in mind that increases in BMD with bisphosphonates account for a small fraction of their efficacy in preventing bone fractures. It is reasonable to repeat BMD measurement in 2 years in patients with osteopenia and in 3 years in patients with normal bone density. Any clinical suggestion of fracture should prompt bone radiographs.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Active metabolites of vitamin D (calcidiol, alfacalcidol, and calcitriol) should not be regarded as the first-line treatment for bone loss after HT. If they are used, frequent monitoring of urine and serum calcium levels is required, because hypercalcemia and hypercalciuria are common and may develop anytime during treatment.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Calcitonin should not be used to prevent early bone loss after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 10: Reproductive Health after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Pregnancy after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;A multidisciplinary team, involving specialists in maternal and fetal medicine, cardiology and transplant medicine, anesthesia, neonatology, psychology, genetics, and social services, is important in the care of pregnant HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The management plan for pregnant HT recipients should be individualized according to the status of the mother and the allograft she received and is best achieved at the primary transplant institution in collaboration with local or referring physicians.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Individual factors in a HT recipient who wishes to become pregnant should be considered, including the risk of acute rejection and infection, review of concomitant therapy that is potentially toxic or teratogenic, and review of the adequacy of graft function. After careful consideration of these individual factors, patients should be counseled on the risks of pregnancy and pregnancy discouraged if graft dysfunction and significant CAV are expected to preclude a successful outcome.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pregnancy in a HT recipient should generally not be attempted sooner than 1 year after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In a HT recipient who wishes to become pregnant, baseline tests should be obtained to determine the patient's cardiac status and should include an electrocardiogram (ECG) and echocardiogram (and coronary angiography if not performed within the previous 6 months) with the option of right-heart catheterization and endomyocardial biopsy (EMB), if clinically indicated.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Baseline assessment of renal and liver function should be obtained in a pregnant HT recipient and frequent monitoring of blood pressure, urine cultures, and surveillance for pre-eclampsia and gestational diabetes should be done.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;CNIs and CS should be continued in a pregnant HT recipient, but MMF (class D) should be discontinued.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Blood levels of CNI should be monitored closely during pregnancy due to large fluctuations in levels during the pregnancy-related changes in plasma and interstitial volume and hepatic and renal blood flow.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequent surveillance for rejection is imperative in a pregnant HT recipient, although surveillance EMB done under fluoroscopy should be avoided. An EMB under echocardiographic guidance or fluoroscopy with leaded patient draping can be performed if necessary.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;The use of AZA (also class D), as a substitute for MMF, is somewhat controversial, and avoidance of both agents in a pregnant HT recipient should be decided on the basis of the balance of maternal and fetal risk.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is uncertain whether the potential risks of drug exposure for the infant outweigh the benefits of breastfeeding, which is therefore not recommended for HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for Contraception after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Before combination hormonal contraception is prescribed, a HT recipient should be screened for risk factors for a hypercoagulable state (a strong family or personal history of thromboembolic events).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Combined hormonal contraception inhibits the cytochrome P-450 (CYP-450) 3A4 pathway, and immunosuppressant drug blood levels should be monitored carefully when starting this therapy in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Barrier methods provide inadequate pregnancy protection and should be used as an adjunct to other methods in HT recipients. They should be recommended for all sexually active adolescents for sexually transmitted infection (STI) prevention.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Intrauterine devices (IUD) have been generally not recommended in HT recipients and, in particular, in nulliparous patients because of the increased risk of IUD expulsion in nulliparous women and because of concerns regarding increased risk of pelvic inflammatory infection and infertility.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Depo-medroxyprogesterone acetate has been associated with decreased bone density and, therefore, is not routinely recommended for HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hormonal contraception should not be prescribed in HT recipients who have significant hypertension, known CAV, estrogen-sensitive cancers, or active liver disease.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Management of Sexually Transmitted Infections&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should obtain a confidential sexual history from adolescent HT recipients and may consider routine referral to an adolescent medicine specialist who will provide thorough and confidential reproductive health care.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Sexually active adolescents and adult HT recipients with multiple partners should be advised to undergo screening for STI, including a complete anogenital examination to screen for anogenital warts, molluscum, herpes simplex virus (HSV), or other lesions at an appropriate clinic at regular intervals.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A complaint of genitourinary symptoms or disclosure of high-risk behavior should trigger a full evaluation for STI in HT recipients. Genitourinary symptoms may also be an indication for empiric antimicrobial therapy while awaiting results of STI screening.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The quadrivalent human papillomavirus (HPV) vaccine may prevent persistent HPV infection, cervical and vulvovaginal cancer precursor lesions, and genital warts secondary to HPV types 6, 11, 16, and 18. Women should receive all 3 doses before HT. There is no contraindication to administering the vaccine to women after HT, although no studies have confirmed immunogenicity or efficacy in this population.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Management of Erectile Dysfunction after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Possible iatrogenic causes of erectile dysfunction (ED) should be identified in HT recipients, and alternative medications should be used where possible.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In HT recipients with ED, use of phosphodiesterase inhibitors can be considered. Concomitant nitrate therapy is contraindicated similarly to the general population.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In HT recipients with ED, consider referral to an ED specialist for possible intra-cavernous injections of prostaglandin E1 if phosphodiesterase inhibitors are ineffective or contraindicated.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 11: Exercise and Physical Rehabilitation after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for Exercise and Physical Rehabilitation after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;The routine use of cardiac rehabilitation with performance of aerobic exercise training is recommended after HT. The short-term benefits of this approach include improvement in exercise capacity and possible modification of cardiovascular risk factors such as obesity, hypertension, and glucose intolerance. There is currently no information on potential long-term benefits.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Resistance exercise is also strongly encouraged in HT recipients to restore BMD and prevent the adverse effects of CS and CNI therapy on skeletal muscle. Resistance exercise should be additive to other therapies for bone mineral loss and muscle atrophy.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Exercise should be encouraged after pediatric HT, although no data on the long-term benefits exist. Exercise has been shown to produce short-term improvements in functional capacity and perhaps to decrease obesity-related morbidity. Specific exercise programs should be tailored to the specific needs and co-morbidities of the individual HT recipient.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 12: Management of Intercurrent Surgery in Heart Transplant Recipients&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on the Management of Intercurrent Surgery in Heart Transplant Recipients&lt;/strong&gt; (See Table 15 in the original guideline document.)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;HT recipients requiring intercurrent surgical procedures should have a full pre-operative assessment in collaboration with the transplant team, particularly in preparation for major procedures requiring general or regional anesthesia.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For many surgical procedures, prophylactic antibiotic administration is now the norm. Protocols may need modification in HT recipients. Aminoglycoside antibiotics and erythromycin are best avoided because of the risk of worsening renal dysfunction when used in combination with cyclosporine (CYA) or tacrolimus (TAC).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;When needed, blood products used in HT recipients should be leukocyte poor. ABO-incompatible infant HT recipients require specialized blood products and must be discussed with the transplant center.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Anesthesia can be safely induced provided that there is clear understanding that the HT is denervated. The resting heart rate is usually higher in HT recipients. Although most allografts have a resting heart rate of approximately 90 beats/min, some have resting sinus rates as high as 130 beats/min, which do not require treatment. It must be remembered that a relative, symptomatic bradycardia that requires treatment will not respond to atropine. Isoproterenol infusion and pacing are the usual modes of management of HT bradyarrhythmias. Although uncommon, the likeliest sustained atrial arrhythmia is atrial flutter. Likewise, the denervated heart is super-sensitive to adenosine, and the use of standard doses to treat atrial tachyarrhythmias may result in prolonged asystole. Amiodarone is recommended as the drug of choice for atrial tachyarrhythmias in HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Care with fluid balance is important because decreased intravascular volume will exacerbate renal dysfunction, and fluid excess may not be well tolerated by HT recipients. For major surgery, central venous pressure (CVP) monitoring may be necessary.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Immunosuppression should not be discontinued or omitted without discussion with the HT team. However, it may be prudent to omit the dose of CNI on the morning of surgery to avoid potentiating the detrimental effect of dehydration on renal function. Thereafter, immunosuppression should be continued as normal. If medications cannot be given orally CYA should be given intravenous (IV) (often as a 6-hour infusion every 12 hours or as a continuous infusion over 24 hours) at a third of the daily oral dose; tacrolimus can be given IV at a dose one-fifth of the total daily oral dose over 24 hours; AZA should be given IV once daily at the same dose as that taken orally; MMF can be given IV at the same dose taken orally.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 13: Return to Work or School and Occupational Restrictions after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Return to Work or School and Occupational Restrictions after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Health care providers should know that return to work for HT recipients is possible, and not passively support the sick role of patients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Return to work should be discussed before HT as the goal of post-operative rehabilitation, and not as an exception.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients should be encouraged to maintain their jobs as long as possible before HT because this facilitates return to work after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Short-term and long-term goals for returning to work should be discussed as part of the discharge planning after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;An employment specialist (e.g., a social worker) should be appointed who can set up a proactive employment atmosphere and facilitate the return to work process after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This employment specialist should (1) perform a formal assessment of the patient's educational backgrounds, skills, beliefs, functional and physical limitations, and former work experiences; (2) formulate a career plan with the patient that may help the patient to enter or rejoin the work force or acquire further vocational training; (3) have knowledge of the job market and collaborate with the HT team in learning which physical limitations of the patient must be taken into account; (4) educate future employers about HT and share insights about an individual patient's abilities and restrictions in view of post-operative rehabilitation.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 14: Return to Operating a Vehicle after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for the Operation of a Vehicle after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I &lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment and discussion of the ability to drive a motor vehicle should be included in the early follow-up of HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gate stability, tremor, and other neurologic abnormalities should be assessed before HT recipients obtain permission to drive.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;If symptomatic bradycardia is present after HT, the implantation of a permanent pacemaker should be considered before driving is permissible.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The absence of severe hypoglycemic events should be ascertained before HT recipients are permitted to drive.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Occupational driving requires that HT recipients meet their country's requirements for occupational driving.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A high level of scrutiny is required for HT recipients requesting to pilot an aircraft due to the risk of sudden death associated with CAV.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 15: Cardiac Retransplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations for Cardiac Retransplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Retransplantation is indicated in children with at least moderate systolic heart allograft dysfunction and/or severe diastolic dysfunction and at least moderate CAV.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;It is reasonable to consider listing for retransplantation those adult HT recipients who develop severe CAV not amenable to medical or surgical therapy and symptoms of heart failure or ischemia.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is reasonable to consider listing for retransplantation those HT recipients with heart allograft dysfunction and symptomatic heart failure occurring in the absence of acute rejection.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is reasonable to consider retransplantation in children with normal heart allograft function and severe CAV.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIb&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with severe CAV not amenable to medical or surgical therapy with asymptomatic moderate to severe left ventricle (LV) dysfunction may be considered for retransplantation.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class III&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adult and pediatric HT recipients with heart allograft failure due to acute rejection or occurring less than 6 months after the first HT and complicated by hemodynamic compromise are inappropriate candidates for retransplantation.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 16: Endocarditis Prophylaxis after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Endocarditis Prophylaxis in Heart Transplant Recipients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;There are insufficient data to support specific recommendations for endocarditis prophylaxis in HT recipients. However, these patients are at risk of acquired valvular dysfunction, and the outcome of endocarditis is so poor in HT recipients that the use of antibiotic prophylaxis for dental procedures is considered reasonable in patients with valvulopathies.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 17: Frequency of Routine Tests and Clinic Visits in Heart Transplant Recipients&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendation on the Frequency of Routine Tests and Clinic Visits in Heart Transplant Recipients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lifelong follow-up by the transplant center is recommended for HT recipients due to (1) the possibility of acute and/or chronic rejection; (2) the chronic use, toxicity, and drug interactions of immunosuppressants and the associated risks for infection and malignancy; and (3) comorbidities requiring specialized monitoring and management.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up for HT recipients should be provided by a multidisciplinary team, including surgeons, cardiologists, nurses, psychologists, social workers, dieticians, and physiotherapists, among many others. Patients and caregivers should recognize that HT requires a life-long commitment to medical care.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The frequency of follow-up visits for HT recipients will depend on the time since HT and the post-operative clinical course.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In case of an uneventful recovery, follow-up visits are best scheduled every 7 to 10 days during the first month after HT, then every 14 days during the second month, monthly during the first year, and every 3 to 6 months thereafter.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The frequency of follow-up should be increased if complications occur, particularly in patients with challenging medical or psychosocial conditions.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ancillary services, including home care nursing, cardiac rehabilitation, psychologic support, nutritional planning, or patient support groups may also be used as resources in the follow-up of HT recipients, with the understanding that providers of community health care services must communicate with the clinicians at the transplant center to ensure that the care delivered complies with the HT center's standards.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Local health professionals should inform the transplant center in the case of the following events: (1) hospitalization for any reason; (2) change in medication, including the addition of any antibiotic, antifungal, or antiviral therapy for confirmed or presumed infection; (3) hypotension or unexplained drop in systolic blood pressure &amp;ge;20 mm Hg from baseline; (4) increase in resting heart rate &amp;gt;10 beats/min over baseline; (5) fever &amp;ge;101&amp;deg;F (38&amp;deg;C) or any unexplained fever &amp;ge;100.5&amp;deg;F for &amp;ge;48 hours (38&amp;deg;C); (6) &amp;ge;2-pound weight gain in 1 week (i.e., 900 g or more); (7) unexplained weight loss of &amp;gt;5 pounds (i.e., 2.3 kg); (8) elective surgery; (9) increased shortness of breath; (10) pneumonia or any respiratory infection; (11) syncope; (12) chest pain other than musculoskeletal symptoms; (13) decline &amp;gt;10% in forced expiratory volume in 1 second; (14) abdominal pain; (15) nausea, vomiting or diarrhea; (16) cerebral vascular event, seizure, or mental status changes.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;In addition to routine outpatient follow-up visits, HT recipients should have more prolonged visits every 1 to 2 years for more detailed clinical assessment.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The purpose of the follow-up visits is to monitor for rejection and screen for adverse events, and may include the following: (1) a complete physical examination; (2) review of the medication and changes to the medication based on the results of the examinations; (3) blood work; (4) echocardiogram; (5) coronary angiography and IVUS (every 1 to 2 years); (6) EMB according to the typical schedule outlined in the chart below; (7) additional education and/or interaction with members of the multidisciplinary team. An example of a typical biopsy schedule for the first year could be:&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Typical Biopsy Schedule for the First Year after HT&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Biopsy 1, 2, 3, 4, and 5&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Weekly&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Biopsy 6, 7, and 8&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 14 days&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Biopsy 9 and 10&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 3 weeks&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Biopsy 11, 12, and 13&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 4 weeks&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Subsequent biopsies during the 1st year after heart transplant (HT)&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Every 5 to 6 weeks&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;This recommendation is addressed in more detail in the National Guideline Clearinghouse (NGC) summary of the International Society for Heart and Lung Transplantation guideline &lt;a href=&quot;/content.aspx?id=45097&quot; title=&quot;Guideline #9794&quot;&gt;Immunosuppression and rejection&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;3&quot;&gt;&#xD;&#xA;    &lt;li&gt;In pediatric practice, far fewer biopsies are performed due to the need for general anesthesia in small children and the difficulties with venous access and bioptome manipulation in small hearts and vessels. There is no consensus on the frequency of biopsy in children. Some centers do no EMB at all, but instead use detailed echocardiographic assessment. Besides scheduled clinic appointments, the patients should be encouraged to contact the transplant center with questions, concerns, or unexpected symptoms.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 18: Psychologic Issues Particularly Related to Adherence to Medical Therapy in Heart Transplant Recipients&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Psychologic Issues after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class IIa&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adherence with the prescribed regimen should be routinely assessed at every HT outpatient clinic visit.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Because there is currently no gold standard for adherence assessment in HT recipients, it is recommended to combine methods to increase accuracy of assessment (e.g., a combination of self-report or parent report in case of children, drug levels assessment, and clinical judgment).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Attention should be given not only to adherence to the immunosuppressive regimen but also to all other health recommendations appropriate for HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Barriers to adherence should be discussed in an open, non-threatening way during visits with HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tailored interventions, in close collaboration with the HT recipient and his or her family, should be considered and their efficacy explored. Strategies that seem most effective include offering education repeatedly, reducing the complexity of the medication regimen, providing feedback on a patient's behavior, and combining strategies.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Strategies to enhance maturity and independence may be particularly helpful in the adolescent HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Because adherence to medical recommendations is a complex issue, health care teams would benefit from training in measuring adherence, discussing its barriers, and implementing adherence-enhancing interventions for HT recipients.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Each HT center should closely collaborate with a specialized nurse or psychologist who can screen and monitor all HT recipients at risk for non-adherence. Investing in specialized staff may result in better transplant outcomes in the long-term, although further studies testing the efficacy of adherence-enhancing interventions are warranted.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Depressive symptoms should be regularly evaluated during follow-up of HT recipients. This can best be done by user-friendly, validated screening instruments. All patients with elevated scores should be referred to specialized treatment.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Each HT team should include a psychologist who is qualified to detect and treat depression. Multidisciplinary treatment teams are better prepared to address psychosocial risk factors for poor outcomes after HT.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Serotonin reuptake inhibitors, particularly citalopram, and new-generation antidepressants (mirtazapine) may be the best choice for HT recipients because they have no significant impact on blood pressure, heart rate, rhythm, or conduction intervals.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Agents that interact with the metabolism of CYA and TAC via the CYP-450 system (e.g., fluvoxamine, nefazodone) should be avoided because they may alter CNI levels.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tricyclic antidepressants (e.g., imipramine, desipramine, amitriptyline, and clomipramine) are associated with cardiovascular toxicity (conduction delay, orthostatic hypotension, and anticholinergic effects) and may lower seizure thresholds, and therefore, their use should be restricted to HT recipients with severe depression refractory to other therapies. Monoamine oxidase inhibitors (MAOIs) should be avoided because of their hypotensive effects, interactions with anesthetic and pressor agents, and need for dietary restrictions. Herbal medicines such as St. John's wort (&lt;em&gt;Hypericum perforatum&lt;/em&gt;) can be harmful because it lowers CYA levels.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: B.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 19: Management of the Transition from Pediatric to Adult Care after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on the Management of the Transition from Pediatric to Adult Care after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Critical milestones to be achieved by pediatric HT recipients before transition to adult care include (1) understanding of and ability to describe the original cause of their organ failure and need for HT (initial education may have been primarily provided to the parents of the HT recipient, and repetition is necessary to ensure understanding of the clinical condition by the HT recipient); (2) awareness of the long and short-term clinical implications of chronic immunosuppression (infection prevention, cancer surveillance, academic and vocational aspirations); (3) comprehension of the impact of HT status on sexuality and reproductive health (impact of pregnancy, effect of medications on fertility, any potential teratogenicity of medications, role of genetic counseling and genetic risk of disease recurrence in offspring, and increased susceptibility to sexually transmitted disease); (4) demonstration of a sense of responsibility for self-care (knowledge of medications, ability to obtain prescription refills, adherence to medication and office visits schedules, ability to independently communicate with health providers, recognition of symptoms and signs requiring immediate medical attention, and understanding of health care coverage and eligibility requirements).&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health care providers should simultaneously prepare the parents for the transition from pediatric to adult care by encouraging independence and self-responsibility in the child.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Practitioners who care for adults should cultivate partnerships with their pediatric colleagues to gain insight into the care of adolescents and the impact of childhood chronic disease on development and management of childhood causes of end-stage organ failure and congenital diseases. Ideal adult site resources also include a dedicated transfer liaison nurse coordinator, a social worker, and a reproductive specialist.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Topic 20: Principles of Shared Care after Heart Transplantation&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Recommendations on Principles of Shared Care after Heart Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Class I&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;The HT team should ensure that other involved physicians know telephone numbers and electronic mail addresses of the HT team to enable contact at all times and guarantee prompt responses to referring physicians' queries.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is helpful for physicians outside the HT team to receive the patient's plan for scheduled HT office visits at the transplant center.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Formal procedures should be instituted to regularly inform the referring physician of clinical results and medical regimens.&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Level of Evidence: C.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Definitions&lt;/strong&gt;&lt;/span&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Level of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;A&lt;/strong&gt;: Data derived from multiple randomized clinical trials or meta-analyses&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;B&lt;/strong&gt;: Data derived from a single randomized clinical trial or large non-randomized studies&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;C&lt;/strong&gt;: Consensus of opinion of the experts and/or small studies, retrospective studies, registries&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class of Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class I&lt;/strong&gt;: Evidence and/or general agreement that a given treatment or procedure is beneficial, useful and effective&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class II&lt;/strong&gt;: Conflicting evidence and/or divergence of opinion about the usefulness/efficacy of the treatment or procedure&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIa&lt;/strong&gt;: Weight of evidence/opinion is in favor of usefulness/efficacy&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class IIb&lt;/strong&gt;: Usefulness/efficacy is less well established by evidence/opinion&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Class III&lt;/strong&gt;: Evidence or general agreement that the treatment or procedure is not useful or effective and in some cases may be harmful&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Improved long-term care and management of heart transplant (HT) recipients including improved survival, decreased rejection rates, and decreased rates of cardiac allograft vasculopathy and adverse effects of immunosuppression&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of immunosuppressive drugs (see Table 14 in the original guideline documents for specific complications of calcineurin inhibitors, mammalian target or rapamycin inhibitors, mycophenolate mofetil, and corticosteroids) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Chronic immunosuppression should be minimized in heart transplant (HT) recipients as possible, particularly in patients at high risk for malignancy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Active metabolites of vitamin D (calcidiol, alfacalcidol, and calcitriol) should not be regarded as the first-line treatment for bone loss after HT. If they are used, frequent monitoring of urine and serum calcium levels is required, because hypercalcemia and hypercalciuria are common and may develop anytime during treatment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The use of azathioprine (also class D), as a substitute for mycophenolate mofetil, is somewhat controversial, and avoidance of both agents in a pregnant HT recipient should be decided on the basis of the balance of maternal and fetal risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Before combination hormonal contraception is prescribed, a HT recipient should be screened for risk factors for a hypercoagulable state (a strong family or personal history of thromboembolic events). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tricyclic antidepressants (e.g., imipramine, desipramine, amitriptyline, and clomipramine) are associated with cardiovascular toxicity (conduction delay, orthostatic hypotension, and anticholinergic effects) and may lower seizure thresholds, and therefore, their use should be restricted to HT recipients with severe depression refractory to other therapies. Herbal medicines such as St. John's wort (&lt;em&gt;Hypericum perforatum&lt;/em&gt;) can be harmful because they lower cyclosporine levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Owing to the potential for precipitating rejection, calcineurin inhibitor (CNI)-free regimens should be used with caution in HT recipients with significant renal insufficiency that persists despite CNI reduction. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Monoamine oxidase inhibitors (MAOIs) should be avoided because of their hypotensive effects, interactions with anesthetic and pressor agents, and need for dietary restrictions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Concomitant nitrate therapy with phosphodiesterase inhibitors is contraindicated similarly to the general population. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Agents that interact with the metabolism of cyclosporine (CYA) and tacrolimus (TAC) via the cytochrome-P450 (CYP-450) system (e.g., fluvoxamine, nefazodone) should be avoided because they may alter calcineurin inhibitor (CNI) levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aminoglycoside antibiotics and erythromycin are best avoided because of the risk of worsening renal dysfunction when used in combination with CYA or TAC. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;It is uncertain whether the potential risks of drug exposure for the infant outweigh the benefits of breastfeeding, which is therefore not recommended for heart transplant (HT) recipients. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Hunt S, Burch M, Bhat G, Canter C, Chinnock R, Crespo-Leiro M, Delgado R, Dobbels F, Grady K, Kao W, Lamour J, Parry G, Patel J, Pini D, Towbin J, Wolfel G. Task Force 3: long-term care of heart transplant recipients. In: the International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010 Aug;29(8):933-44.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2010 Aug" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="International Society for Heart and Lung Transplantation - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;International Society for Heart and Lung Transplantation (ISHLT)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Task Force 3 on Long-term Care of Heart Transplant Recipients&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force 3 Chair&lt;/em&gt;: Sharon Hunt, MD&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Co-Chair&lt;/em&gt;: Michael Burch&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Contributing Writers&lt;/em&gt;: Geetha Bhat, MD; Charles Canter, MD; Richard Chinnock, MD; Marisa Crespo-Leiro, MD; Reynolds Delgado, MD; Fabienne Dobbels, PhD; Kathleen Grady, PhD; Walter Kao, MD; Jaqueline Lamour, MD; Gareth Parry, MD; Jignesh Patel, MD; Daniela Pini, MD; Jeffrey Towbin, MD; Gene Wolfel, MD&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Writing Group makes every effort to avoid any actual or potential conflicts of interest that might arise as a result of an outside relationship or personal interest of a member of the writing panel. Specifically, before being appointed by the Committee, all the proposed members of Writing Group are asked to provide disclosure statements of all relationship that might be perceived as real or potential conflicts of interest. Once they have verbally accepted to become members of the Writing Group, they are asked to sign a written consent form as well as a form disclosing any potential conflict of interest. The disclosure form must be updated if any changes occur during the elaboration of the document.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each writing group member and editorial oversight committee member completed a disclosure form that is maintained on file at the International Society for Heart and Lung (ISHLT) headquarters. The conflict of interest disclosures are also provided in the &lt;a href=&quot;http://www.jhltonline.org/article/S1053-2498(10)00358-X/fulltext&quot; title=&quot;Journal of Heart and Lung Transplantation Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available on the &lt;a href=&quot;http://www.jhltonline.org/article/S1053-2498(10)00358-X/fulltext&quot; title=&quot;Journal of Heart and Lung Transplantation Web site&quot;&gt;Journal of Heart and Lung Transplantation Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;International Society for Heart and Lung Transplantation (ISHLT) Standards and Guidelines Development Protocol. Electronic copies: Available from the &lt;a href=&quot;http://www.ishlt.org/ContentDocuments/ISHLT_Standards_and_Guidelines_Development_Protocol.pdf&quot; title=&quot;International Society for Heart and Lung Transplantation (ISHLT) Web site&quot;&gt;International Society for Heart and Lung Transplantation (ISHLT) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 17, 2013. The information was verified by the guideline developer on September 3, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
